Follow the people · Insider

PC

Pablo J. Cagnoni

Insider · President, Global Head of R&D · INCY

Pablo J. Cagnoni files insider transactions with the SEC as a president, global head of r&d of Incyte (INCY). We hold 7 disclosed purchases and sales filed since 15 December 2006, 4 of them in the last 90 days.

  • Files forINCY
  • Disclosed buys and sells7 in all, 4 in the last 90 days
  • Last disclosure20 August 2026

Positions held

7 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 5 June 202319 August 2026President, Global Head of R&D · Incyte (INCY)53 Form 4 lines · source: SEC Form 4
  • Filed 25 June 20204 June 2024Director · Fusion Pharmaceuticals (FUSN)9 Form 4 lines · source: SEC Form 4
  • Filed 31 October 20181 February 2023CEO and President · Rubius Therapeutics (RUBY)20 Form 4 lines · source: SEC Form 4
  • Filed 18 October 201619 November 2019Director · CRISPR Therapeutics AG (CRSP)19 Form 4 lines · source: SEC Form 4
  • Filed 11 March 20131 October 2013EVP, Global R&D and Tech Ops · Onyx Pharmaceuticals (ONXX)4 Form 4 lines · source: SEC Form 4
  • Filed 19 March 200730 September 2009Sr. VP, Chief Medical Officer · Allos Therapeutics (ALTH)9 Form 4 lines · source: SEC Form 4
  • Filed 13 December 200613 December 2006VP & Chief Medical Officer · Osi Pharmaceuticals (OSIP)1 Form 4 line · source: SEC Form 4

Everything they disclosed

115 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.